Global Respiratory Complications Therapeutics Market to 2022 - Innovative Pneumonia and Pulmonary Arterial Hypertension Therapies Dominate Varied Disease Market

ResearchMoz added Latest Research Report titled " Global Respiratory Complications Therapeutics Market to 2022 - Innovative Pneumonia and Pulmonary Arterial Hypertension Therapies Dominate Varied Disease Market " to it's Large Report database.

The respiratory therapy area consists of indications that affect the respiratory system in various ways, including the scarring of lung tissue and excessive production of mucus in the airways, thereby decreasing lung function. The causes of respiratory disorders vary significantly between indications, with potential causes including infection, vascular damage or dysfunction, aging, environmental stressors such as pollution, and genetic predisposition.

The treatment landscape for respiratory disorders has traditionally been dominated by small molecule therapies that treat the disease symptoms rather than the cause. This means that treatment options can be diverse in terms of their targets and mechanisms of action. This is most notable in cystic fibrosis (CF), where patients may be prescribed a combination of drugs from several treatment categories, including mucolytic agents, bronchodilators and antibiotics. The chronic obstructive pulmonary disease (COPD) and asthma treatment landscapes employ similar symptomatic treatments, including bronchodilators and inhaled corticosteroids.

Request for Sample PDF of Premium Research Report with TOC: http://www.researchmoz.us/enquiry.php?type=S&repid=1049124

The respiratory therapy area contains numerous primary indications, including asthma, COPD, CF and idiopathic pulmonary fibrosis (IPF), which have large prevalent populations. In addition, there are many secondary respiratory conditions that have smaller prevalent populations yet significant unmet clinical needs. This report focuses on these secondary respiratory conditions, particularly pneumonia, respiratory syncytial virus (RSV), pulmonary arterial hypertension (PAH) and tuberculosis (TB).

A major cause of secondary respiratory disease is infections caused by bacteria or viruses. Bacterial infections, such as pneumonia and TB, and viral infections, such as RSV, cause infection of the lungs. The immune system response to these infections causes inflammation that interferes with the ability of the lungs to function. Cardiovascular problems also represent another major cause of respiratory complications. PAH in particular represents a profound risk factor for cardiovascular events in the pulmonary vascular system, including pulmonary embolism.

Browse more details @ http://www.researchmoz.us/global-respiratory-complications-therapeutics-market-report.html

Table of Contents

1 Table of Contents
1 Table of Contents 5
1.1 List of Tables 7
1.2 List of Figures 8

2 Introduction 10
2.1 Therapy Area Introduction 10
2.2 Symptoms 10
2.2.1 Pneumonia 10
2.2.2 RSV 10
2.2.3 PAH 11
2.2.4 Tuberculosis 11
2.3 Diagnosis 11
2.3.1 Pneumonia 11
2.3.2 RSV 11
2.3.3 PAH 12
2.3.4 Tuberculosis 12
2.4 Etiology and Pathophysiology 12
2.4.1 Pneumonia 14
2.4.2 RSV 14
2.4.3 PAH 15
2.4.4 Tuberculosis 16

About ResearchMoz

ResearchMoz is the world's fastest growing collection of market research reports worldwide. Our database is composed of current market studies from over 100 featured publishers worldwide. Our market research databases integrate statistics with analysis from global, regional, country and company perspectives. ResearchMoz's service portfolio also includes value-added services such as market research customization, competitive landscaping, and in-depth surveys, delivered by a team of experienced Research Coordinators.

Contact Us:

Mr. Nachiket Ghumare
90 State Street, Albany NY, United States - 12207
Tel: +1-518-621-2074 / Tel: 866-997-4948 (Us-Canada Toll Free)
Email: sales@researchmoz.us
Follow us on LinkedIn at: http://bit.ly/1TBmnVG
Follow me on Blogger at: http://healthcare-research-report.blogspot.in/

This release was published on openPR.